Phase 2 N=8 Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Breast Cancer
Primary: Number of Participants Who Had a Pathological Complete Response (pCR) — 0; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
Breast Cancer
Primary: Number of Participants That Achieved Pathologic Complete Response (CR) — 11 Participants
Phase 2 N=26 Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
Breast Neoplasms
Primary: Part A: Clinical Benefit (CB) Assessed by Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for at Least 6 Months Using the Response Evaluation…
Phase 2 N=110 Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 18 percentage of participants
Phase 2 N=22 TKI258 for Metastatic Inflammatory Breast Cancer Patients
Breast Cancer
Primary: Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of Participants — 0; 0; 1 participants
Phase 2 N=23 Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Breast Cancer
Primary: Percentages of Participants With Pathologic Complete Response — 48 percentage of participants
Phase 2 N=123 Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response — 23 Participants
Phase 2 N=20 Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Recurrent Breast Cancer · Metastatic Breast Cancer
Primary: Ruxolitinib Maximum Tolerated Dose (MTD) [Phase I] — 15 mg
Phase 2 N=215 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
Breast Cancer
Primary: Number of Patients With Pathological Complete Response Rate — 35; 24 Participants — p=0.019
Phase 2 N=163 Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
Neoplasms, Breast
Primary: Number of Participants With Overall Response (OR), Defined as Those Participants Achieving Complete Response (CR) or Partial Response (PR), Assessed Per Response…
Phase 2 N=56 A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response Following Principle Investigator Review — 23.2 percentage of participants
Phase 2 N=25 Partial Breast Irradiation With Chemotherapy
Breast Cancer
Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants
Phase 2 N=10 Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 4.8 months
Phase 2 N=40 Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Breast Cancer
Primary: Complete Response Rate — 2; 8 Participants
Phase 2 N=168 Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response Rate (pCR) — 27 participants
N/A N=324 Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer
Ductal Breast Cancer
Primary: Feasibility and Local Control of Early Breast Cancer Treated by Partial Breast Irradiation Using Different Radiation Doses Determined by Completion. — 98; 101; 124…
Phase 2 N=103 Ixabepilone + Carboplatin Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.4; 34 percentage of participants
N/A N=66 Intraoperative Radiotherapy After Local Recurrence in Breast Cancer
Breast Carcinoma
Primary: The Tolerance of RIOP (Intra Operative Radiotherapy) in Patients With Delayed Local Recurrences, After a Second Conservative Treatment of Breast Cancer — 34; 19…
Phase 2 N=6 Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Metastatic Triple Negative Breast Cancer
Primary: Objective Response Rate (ORR) — 0; 1; 1; 4 Participants
N/A N=30 Post-operative Radiation With IMRT in the Management of Stage IIB-III Breast Cancer
Breast Cancer
Primary: Acute Radiation Effects (Less Than 90 Days Post Treatment) — 0 Participants
Phase 2 N=270 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Breast Cancer
Primary: Local Recurrence — 3.1 percentage of participants
N/A N=90 Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
N/A N=31 Single Fraction Elderly Breast Irradiation (SiFEBI)
Breast Cancer
Primary: Rate of Acute Toxicity Within 180 Days of IPAS Mono Split Postoperatively in Patients Aged at Least of 70 Years With Breast Cancer at Low Risk of Local Recurrence (Low…
Phase 2 N=69 Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response
Breast Cancer
Primary: Test the Clinical Effectiveness of Concurrent Paclitaxel and Radiation in a Multiethnic Cohort
Phase 2 N=100 Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer
Breast Neoplasms
Primary: Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan — 100; 100 percentage…
Phase 2 N=50 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
Estrogen Receptor-negative Breast Cancer · Estrogen Receptor-positive Breast Cancer · Inflammatory Breast Cancer
Primary: Event-free Survival — 11; 9 Participants
Phase 2 N=58 Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 27 participants
Phase 2 N=24 SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
Breastcancer · Breast Neoplasm
Primary: Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety] — 24; 11; 8; 7 Participants
Phase 2 N=50 BKM120 For Triple Negative Breast Cancer
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Phase 2 N=52 A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
Breast Cancer
Primary: Percentage of Participants With a Pathological Complete Response (PCR) According to the Sataloff Classification — 63.46 percentage of participants